Background: Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can cause intolerable adverse events in patients with non-small cell lung cancer (NSCLC) and may be prescribed at a lower dose. Conclusion: Patients who initiated TKI therapy at a RD did not have different PFS and 15-month survival outcomes than patients who initiated TKI therapy at the FDA SD. READ ARTICLE
Journal of Pharmacy Practice DOI:10.1177/0897190019840596
Authors: Emily Miao, Nagashree Seetharamu, Kevin Sullivan, Stephen Eng, Chung-Shien Lee